BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17610503)

  • 1. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice.
    Justesen S; Buus S; Claesson MH; Pedersen AE
    Immunology; 2007 Nov; 122(3):326-34. PubMed ID: 17610503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
    Shibagaki N; Udey MC
    Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.
    Viehl CT; Tanaka Y; Chen T; Frey DM; Tran A; Fleming TP; Eberlein TJ; Goedegebuure PS
    Breast Cancer Res Treat; 2005 Jun; 91(3):271-8. PubMed ID: 15952060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
    Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
    Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
    Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
    Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
    Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
    Kuball J; Schuler M; Antunes Ferreira E; Herr W; Neumann M; Obenauer-Kutner L; Westreich L; Huber C; Wölfel T; Theobald M
    Gene Ther; 2002 Jul; 9(13):833-43. PubMed ID: 12080377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
    Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
    J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tat fusion protein-based tumor vaccine for breast cancer.
    Viehl CT; Becker-Hapak M; Lewis JS; Tanaka Y; Liyanage UK; Linehan DC; Eberlein TJ; Goedegebuure PS
    Ann Surg Oncol; 2005 Jul; 12(7):517-25. PubMed ID: 15889213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
    Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
    Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.